Download the ESMO 2012 Abstract Book - Oxford Journals

Annals of Oncology
1627 RETROSPECTIVE ANALYSIS OF CANCER AND
CHEMOTHERAPY INDUCED ANAEMIA TREATED WITH
FERRIC CARBOXYMALTOSE ONLY, AN INTRAVENOUS IRON
THERAPY
B. Tschechne 1 , S. Broszeit-Luft 2 , O. Harlin 3 , W.O. Jordan 2 and H. Zakaria 4
1 Haematologisch-Onkologische Praxis Neustadt, Neustadt a. Rbge., GERMANY,
2 Haematologisch-Onkologische Praxis Lehrte, Lehrte, GERMANY, 3 Vifor Pharma
Deutschland GmbH, München, GERMANY, 4 NewConceptOncology GmbH,
Lehrte, GERMANY
Chemotherapy induced anaemia is often treated with ESAs and/or blood
transfusions. Oral or intravenous iron substitution represent alternatives for both
cancer and chemotherapy induced anaemia. Current discussions focus on
intravenous treatment to increase Hb levels in cancer patients, as oral treatments are
often associated with limited response rates and gastrointestinal side effects. This
retrospective, single centre analysis investigates the effectiveness of an iv iron
compound, ferric carboxymaltose (Ferinject® [FCM]) as the only anaemia treatment
in an unselected, routinely treated anaemic cancer patient population between 2009
and 2012. Patients fulfilling the following criteria were included in the analysis:
malignant cancer diagnosis, anaemia, FCM treatment ≧ 4 weeks, complete available
documentation ≧ 12 weeks, no ESA or other iron medication and no blood
transfusion during the observation period. At baseline, sex, age, tumour history,
anti-tumour treatment and history of anaemia treatment during the four weeks prior
the retrospective analysis were recorded. Modalities of FCM treatment and serum
levels of available relevant laboratory parameters (e.g. Hb, transferrin saturation
[TSAT], ferritin, haematocrit) were recorded at baseline and throughout the
observation period. Treatment response, tolerability and adverse reactions for a total
of 59 cancer patients were investigated. The median age was 61 (20-91) years, of
these 14 were male and 45 female. During the FCM therapy, 52 patients were not
treated actively for cancer and 7 patients were on anticancer treatment. Median Hb
increase was 2.0 g/dl compared to baseline (range: 0 to 6.2 g/dl). Patients received on
average 336 mg iron (range: 100-1700mg). No adverse events related to FCM were
recorded. The results of our retrospective analysis demonstrate the safety and
effectiveness of FCM therapy in correction of anaemia in cancer patients prior,
during or after completed chemotherapy. More long-term data on FCM exposure in
cancer patients with iron deficiency are needed in order to characterize which
patients benefit most from this therapy and to determine optimal dosing and
frequency of FCM use.
Disclosure: B. Tschechne: I am a member of the Advisory Board of Vifor Pharma
DeutschlandO. Harlin: employee of Vifor Pharma GermanyH. Zakaria: The data
analysis shown was sponsored by Vifor Pharma DeutschlandAll other authors have
declared no conflicts of interest.
1628 ANEMIA POINT PREVALENCE IN PATIENTS RECEIVING
CHEMOTHERAPY IN 56 CENTERS IN ITALY AND AUSTRIA
L. Merlini 1 , G. Carteni 2 , S. Iacobelli 3 , C. Stelitano 4 , M. Airoldi 5 , P. Balke 6 , F. Keil 7 ,
F. Haslbauer 8 , L. Belton 9 and B. Pujol 10
1 Medical Oncology, Ospedale Civile S. Bortolo, Vicenza, ITALY,
2 Onco-Hematology, Azienda Ospedaliera Cardarelli, Napoli, ITALY, 3 Medical
Oncology, Ospedale Clinicizzato SS.Annunziata, Chieti, ITALY, 4 Hematology,
Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, ITALY, 5 Medical
Oncology, Azienda Ospedaliero Universitaria Le Molinette, Torino, ITALY, 6 1st
Medical Department, General Hospital St. Pölten and Karl Landsteiner Institute of
Oncology, St. Pölten, AUSTRIA, 7 Hematology-Oncology, Landeskrankenhaus
Leoben, Leoben, AUSTRIA, 8 Internal Medicine, Landeskrankenhaus
Vöcklabruck, Vöcklabruck, AUSTRIA, 9 Biostatistics, Amgen Ltd, Uxbridge,
UNITED KINGDOM, 10 Haematology/Oncology, Amgen Europe, Zug,
SWITZERLAND
Purpose: To evaluate the point prevalence of anemia in patients with non-myeloid
tumors being treated with chemotherapy (±radiotherapy) in a clinical practice setting.
Methods: This was a cross-sectional, observational survey. Centers had to prespecify
a single day, during a 4-month enrollment window, to report specific data collected
as part of normal clinical practice for patients attending in relation to chemotherapy
treatment. Data for all centers/consenting patients were included in the analyses. The
primary endpoint was the point prevalence of anemia as determined using a
prespecified algorithm, which defined a patient as anemic based on 1) hemoglobin
(Hb) ≤10 g/dL on/within 3 days prior to visit, 2) ongoing anemia treatment at visit,
or 3) physician diagnosis of anemia together with ≥1 anemia symptom at visit.
Reasons for visit, patient demography, tumor type, systemic chemotherapy, Hb levels,
and consequences of anemia, were secondary endpoints. Patients provided informed
consent where required by local regulations.
Results: Between 18/11/2010-18/3/2011, data for 1412 patients were collected (Italy n
= 1130 [80%]; Austria n = 282 [20%]). Of these, 49% were men, median age was 65
years and most (80%) had solid tumors (colorectal: 18%; breast: 18%; lung: 14%;
prostate: 3%; other solid tumors: 28%). Overall, 57% of patients had received ≤3
chemotherapy cycles. The point prevalence of anemia was 32% (95% CI: 29.4%, 34.2%);
14% of patients were deemed anemic based on Hb levels ≤10 g/dL, 9% based on
evidence of anemia treatment and 8% based on physician assessment of anemia
together with ≥1 anemia symptom. Overall, 82% of patients had Hb data; the mean
(SD) Hb level was 11.7 (1.7) g/dL. 32% of patients had anemia symptoms, the most
common were fatigue (28%), depression (9%) and dyspnea (8%). Few patients (4%) had
had their current chemotherapy cycle delayed due to anemia. On visit day or ≤28 days
prior, 6% of patients had evidence of whole blood or red blood cell transfusion, 13%
had evidence of erythropoiesis-stimulating agent use and 6% had evidence of iron use.
Conclusions: In this survey one-third of patients with non-myeloid tumors
undergoing chemotherapy were found to be anemic on the prespecified study day.
Disclosure: L. Belton: Contract worker for Amgen Ltd, B. Pujol: Employed by
Amgen EuropeAll other authors have declared no conflicts of interest.
1629 HIGH PREVALENCE AND INCIDENCE OF ANAEMIA IN
CANCER PATIENTS IN SPAIN
P. Gascón 1 , A. Casas 2 , J. Muñoz 3 , J. De Castro 4 , V. Alberola 5 , M. Cucala 6 and
F. Barón 7
1 Medical Oncology Department, Hospital Clínic i Provincial de Barcelona,
Barcelona, SPAIN, 2 Medical Onology Department, Hospital Virgen del Rocío,
Sevilla, SPAIN, 3 Medical Oncology Department, Hospital Dr. Peset, Valencia,
SPAIN, 4 Medical Oncology Department, Hospital La Paz, Madrid, SPAIN,
5 Medical Oncology Department, Hospital Arnau de Vilanova, Valencia, SPAIN,
6 Medical Advisor, Vifor Pharma España, Barcelona, SPAIN, 7 Medical Oncology
Department, Complejo hospitalario Universitario de Santiago de Compostela,
Santiago de Compostela, SPAIN
Background: Anaemia is a frequent complication in cancer patients. This
haematological abnormality may be related to cancer itself and/or induced by
chemotherapy. The objective of the present study was to describe the prevalence of
anaemia in treatment-naïve patients with solid tumours, the incidence of anaemia
after four months of cancer treatment and anaemia management.
Methods: Multicenter, prospective and observational study that included newly
diagnosed cancer patients. Data on anaemia parameters and its management were
collected at baseline and after four months of cancer treatment. The primary
outcome was the proportion of patients with anaemia defined as a haemoglobin (Hb)
concentration